Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
Items 501–600 of 808
Sobh, S., Itani, R., Hammour, K. A., & Farha, R. K. A. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001312 · Cited by 2
Liu, J., Zhao, Y., Jianping, Z., Liang, G., Yang, Y., Yu, L., & Yu, Z. (2025) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2025.05.003 · Cited by 2
Abusamra, L., Laufer, N., Rolón, M. J., Aronson, S., & Sisto, A. E. (2025) · Actualizaciones en Sida e Infectología · doi:10.52226/revista.v33i118.369 · Cited by 2
Liu, T., Li, G., Yue, H., & Liu, X. (2023) · Intelligent Pharmacy · doi:10.1016/j.ipha.2023.11.003 · Cited by 2
The role of phytomedicine in combating antimicrobial resistance
Akhtar, J. (2024) · Annals of Phytomedicine An International Journal · doi:10.54085/ap.2024.13.1.1 · Cited by 2
Strategies for Updating Piperacillin-Tazobactam Breakpoints
Bobenchik, A. M. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.00042-23 · Cited by 2
Oktariana, D., Sutrisno, V. S., Siahaan, M. E. F., Liana, P., & Hayati, L. (2022) · Jurnal Kedokteran dan Kesehatan Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya · doi:10.32539/jkk.v9i1.188 · Cited by 1
Önal, U., Akyol, D., Kaya, A., Başkol, D., Kenanoğlu, O. B., Şanlıdağ, G., Önal, A. U., Avşar, C. B., Vahabi, M. M., Memetali, S. C., et al. (2023) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-023-04660-3 · Cited by 1
XUỐNG THANG KHÁNG SINH Ở BỆNH NHÂN NẶNG: KHOẢNG TRỐNG GIỮA LÝ THUYẾT VÀ THỰC HÀNH
Võ, P. M. T., Trần, T. A. T., & Nguyễn, T. V. (2023) · Tạp chí Y Dược học Cần Thơ · doi:10.58490/ctump.2023i67.2191 · Cited by 1
Rausch, E. P., Alby, K., & Wilson, W. S. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2023.137 · Cited by 1
D’souza Adelyn, S., Rachana, S., & B., P. A. K. (2024) · Mediterranean Journal of Infection Microbes and Antimicrobials · doi:10.4274/mjima.galenos.2024.23031.2 · Cited by 1
Hernández‐Chico, I., Rodríguez‐Guerrero, E., Ruíz, M. E., Navarro‐Marí, J. M., & Fernández, J. G. (2024) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.25036 · Cited by 1
“…to the 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections of the Infectious Diseases Society of America (IDSA) [23], traditional noncarbapenem β-lactam agents (piperacillin-tazobactam, ceftazidime, cefepime [FEP], aztreonam) are preferred to treat P. aeruginosa…”
BackgroundThe Rise of Irrational Antimicrobial Combinations: Need for Clinical Jurisprudence?
Kundu, R., Baronia, T., & Sathe, P. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24718 · Cited by 1
Seales, C. C., Welch, T., & Seifert, C. F. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241263067 · Cited by 1
Karbapenem Dirençli Enterobacterales Bakteri İzolatlarında Antibiyotik Duyarlılığı
Kazar, A., Özbek, E., Kaydaş, S., & Atmaca, S. (2024) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.1552632 · Cited by 1
Clark, J. A., Burgess, D. S., & Moga, D. C. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2024.445 · Cited by 1
Charoensareerat, T., Bunrit, P., Phanpoka, S., Netthanomsak, T., Rungkitwattanakul, D. “., Pattharachayakul, S., Srisawat, N., & Chaijamorn, W. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154946 · Cited by 1
Sathyanarayana, P., Sharadadevi Mannur, Y., Mudigubba, M. K., & Lingaiah, M. (2024) · Anti-Infective Agents · doi:10.2174/0122113525347025241015053800 · Cited by 1
Infected chronic retroperitoneal fluid collection following anterior lumbar interbody fusion
Hasegawa, S., Prasidthrathsint, K., & Non, L. R. (2024) · BMJ Case Reports · doi:10.1136/bcr-2024-262382 · Cited by 1
Vlase, C.-M., Iancu, A. V., Ștefan, C. S., Draghiev, I., Dumitru, C. N., Nistor, A., & Arbune, M. (2024) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.1.7 · Cited by 1
Uzunöner, Y., Kansak, N., & Aksaray, S. (2024) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2024.02395 · Cited by 1
Roshani, D., Ramazanzadeh, R., Barzegar, S., Arzanlou, M., & Mansouri, M. (2024) · Motaleat-e Tatbiqi-e Honar · doi:10.61186/jommid.12.3.179 · Cited by 1
Malik, N., Sultan, A., Nizamuddin, S., & Shameem, F. (2024) · Infectious Diseases Journal of Pakistan · doi:10.61529/idjp.v33i3.280 · Cited by 1
“23,24 Considering the results of the present investigation, we recommend that fosfomycin and nitrofurantoin may be considered as empirical antibiotic choices for patients at risk of developing UTIs caused by carbapenem-resistant Enterobacterales, pending confirmation through culture results.”
Jiang, L., Fang, J., Zhang, J., Zhang, K., Yue, J., Dong, K., Shen, J., Qiu, Y., & Yu, W. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10760-6 · Cited by 1
“Among Citrobacter spp. , Cfr showed moderate to high risk for clinically significant AmpC production [8].”
Moon, S., Yi, J., Ko, M. K., Sim, Y. K., & Kim, K. (2025) · Antibiotics · doi:10.3390/antibiotics14070649 · Cited by 1
“MEV is effective against KPC-producing isolates but not against MBLs or most OXA-type carbapenemases [13].”
InfluentialCanadian impact of CLSI aminoglycoside breakpoint changes for selected gram-negative bacteria
Avery, E. G., Laughlin, T., Brown, K. A., Matukas, L. M., & Leung, E. (2025) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2025.10035 · Cited by 1
Wang, S., Lin, Y.-C., Chan, M.-C., Yang, K., Sheu, C., Wu, B., Huang, W.-H., Feng, J., Chen, C.-M., Weng, Z., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11205-w · Cited by 1
“Cefoperazone-sulbactam is another β-lactam and β-lactamase inhibitor-containing sulbactam in addition to ampicillin-sulbactam, which plays a dominant role in treating CRAB infection in the recent guideline [3].”
InfluentialKang, C.-D., Marsh, K. L., Siegfried, J., Decano, A., Rick, L., Mazo, D., Thompson, C. N., Paperno, E., & Dubrovskaya, Y. (2025) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001473 · Cited by 1
Uzuriaga, M., Caméléna, F., Yuste, J. R., Fernandes, P., Leiva, J., Berçot, B., & Amarsy, R. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.116987 · Cited by 1
Curry, B. N., Singh, N., Gross, A. E., Watkins, J. V., Ozer, E. A., Karunanidhi, A., Sherwood, K., Obanor, O., Ismail, N., Hauser, A. R., et al. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107633 · Cited by 1
Tebano, G., Campoli, C., Meschiari, M., Contadini, I., Grasselli, S., Lazzaretti, C., Maritati, M., Raumer, L., Rinaldi, M., Rossi, N., et al. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05293-4 · Cited by 1
Tian, B., Bao, H., Yang, X., Yu, R., Lyu, M., Liu, W., Huang, X., & Ding, Q. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11597-9 · Cited by 1
“Multidrug-resistant(MDR) is defined as being insensitive to ≥ 1 agent in ≥ 3 antimicrobial categories(Fluoroquinolones, Cephalosporins, β-Lactamase Inhibitors, Carbapenems, Aminoglycosides) [17–19].”
Aquino, K., Román, L., Larrea, K., & Gaona, D. E. Z. (2025) · Microbes Infection and Chemotherapy · doi:10.54034/mic.e2514 · Cited by 1
Kurdi, A., Gill, H., MacLeod, T., Sorensen, J. L., Hausner, G., & Kumar, A. (2025) · Canadian Journal of Microbiology · doi:10.1139/cjm-2025-0048 · Cited by 1
Torres, R. D. S. G., Barreto, E. S., RIBEIRO, F. F., NICOLINI, P., Beranger, R. W., Sofka, D. C. K., & Ricieri, M. C. (2025) · Journal of Hospital Pharmacy and Health Services · doi:10.30968/jhphs.2025.164.1286 · Cited by 1
Lavoie, T., Sierra, T., Daffinee, K. E., Pogue, J. M., Achour, B., & LaPlante, K. L. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00906-25 · Cited by 1
Zhang, R., Qin, Y., Lv, Y., & Zhang, Y. (2025) · Journal of International Medical Research · doi:10.1177/03000605251394839 · Cited by 1
Maeda, T., Harada, S., Nakase, D., Nakamura, Y., Mori, T., Kashiwagi, K., Sato, T., Miyazaki, T., & Sasaki, Y. (2025) · Cureus · doi:10.7759/cureus.97980 · Cited by 1
“Given the global increase in multidrug-resistant organisms, including ESBL-producing bacteria [16], such risk stratification can aid in the optimization of antimicrobial stewardship and help prevent the emergence of further resistance, particularly carbapenem-resistant Enterobacterales.”
Sadaka, Y., Nakajima, K., Sasaki, Y., Tsurugaya, M., Oida, Y., Soda, M., Hirashita, T., Inoue, K., Takahashi, Y., Yokoi, T., et al. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00535-1 · Cited by 1
“However, the international guidelines [10, 11] have not recommended the use of CMZ for ESBL-E-induced UTIs, probably due to a lack of evidence.”
The Impact of Pharmacist Involvement in Therapeutic Drug Monitoring on Clinical Outcomes
Alanazi, M. J. O., Alruwaili, M. S. I., Alhamed, T. K. O., Alanazi, M. M. M., Alruwaili, R. S., Alanazi, A. H. A., Alhazmi, T. F. K., Aldossari, M. A., Otaibi, K. B. M. A., Alayyaf, R. A., et al. (2024) · International Journal of Computational and Experimental Science and Engineering · doi:10.22399/ijcesen.4674 · Cited by 1
“More importantly, these process improvements translate into tangible clinical benefits, such as lower rates of nephrotoxicity with aminoglycosides, fewer seizures in patients on antiepileptics, and more stable immunosuppression in transplant recipients [7].”
Wei, Q.-Y., Shen, W., Chen, Z., Chen, X.-X., Xu, F., & Fan, H. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s577270 · Cited by 1
Imoto, W., Abe, J., Sakurai, N., Kawamoto, K., YAMADA, K., Kaneko, Y., & Kakeya, H. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00944-25 · Cited by 1
Araújo-Andrade, L., Mota, B., Silva, I., Rogeiro, A., Nogueira, P., Silva, A., Pereira, P. A., Madeira, M. D., & Cardoso, A. (2026) · Antibiotics · doi:10.3390/antibiotics15020218 · Cited by 1
“The emergence of multidrug-resistant bacteria and guidelines in antimicrobial stew-ardship have reinforced the importance of carbapenems in clinical practice and highlighted the need for responsible antibiotic prescription [5,6].”
A systematic review of data on the resistance of uropathogens to sulopenem
Falagas, M. E., Kontogiannis, D. S., Ragias, D., & Filippou, C. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05420-9 · Cited by 1
GELİŞİGÜZEL, G., Demircan, Ş. A., Aysın, M., Kılıç, E. K., Yağcı, S., KINIKLI, S., & Berkem, R. (2026) · Antibiotics · doi:10.3390/antibiotics15020229 · Cited by 1
“This observation is consistent with previous reports indicating that community-onset CRE infections are often linked to prior healthcare exposure, including recent hospitalization, dialysis, and cumulative antibiotic use [24].”
Pranjic, A., Patel, U. C., Vu, T.-H. T., Cao, L., Vivo, A., & Evans, C. T. (2026) · American Journal of Infection Control · doi:10.1016/j.ajic.2026.03.017 · Cited by 1
Moreira, N. K., Mott, M. P., Dornelles, L. S., Constante, C. C., Lutz, L., Barth, P. O., Paiva, R. M., Barth, A. L., & Caierão, J. (2026) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2026250135 · Cited by 1
Toh, C. C., Lee, J. L., Makmor‐Bakry, M., Shah, N. M., & Saffian, S. M. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-06948-w · Cited by 1
Rao, J., Stornelli, N. K., McDaniel, L. F., Zhao, Y., de la Espriella, M. G., Faulhaber, J. R., Todd, S. M., Lahmers, K. K., & Jensen, R. V. (2026) · Applied Sciences · doi:10.3390/app16083803 · Cited by 1
KAYGISIZ, G., Çetin, E. S., Şirin, M. C., & Arıdoğan, B. C. (2026) · Mikrobiyoloji Bulteni · doi:10.5578/mb.202602141 · Cited by 1
Management of severe infections by multi-resistant Gram-negative bacteria in critically ill patients
Garnacho‐Montero, J., Adriaensens-Pérez, M., Aldabó-Pallás, T., Anaya-Carrión, N., Andaluz‐Ojeda, D., Cantón‐Bulnes, M. L., PASCALE, G. D., Fernández-Delgado, E., Póvoa, P. M. S. R., Galleymore, P. R., et al. (2026) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2026.502443 · Cited by 1
Suárez‐Casillas, P., Mejías-Trueba, M., Alemany, I. M., Amuedo, L. N., Segovia, J. P., González, A. D. A., Márquez, R. L., Palacios-Baena, Z. R., Carmona-Caballero, J. M., Oliva, J. M. S., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050549 · Cited by 1
“This classification provides a more clinically relevant assessment of resistance compared to traditional MDR/XDR/CR definitions, as it reflects the absence of safe and effective standard treatments [8,9].”
Managing multidrug resistant Gram-negative bacteraemia in immunocompromised hosts
Bonazzetti, C., Toschi, A., & Giannella, M. (2026) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001205 · Cited by 1
Popescu, R.-I., Toma, C., Petca, R., Mareș, C., Ostafi, L., Petca, A. T., & Jinga, V. (2026) · Microorganisms · doi:10.3390/microorganisms14061236 · Cited by 1
“Large surveillance studies have reported lower resistance rates compared to our findings [25–27].”
Dunne, Z., Oueslati, S., Volland, H., & Naas, T. (2026) · Diagnostics · doi:10.3390/diagnostics16121818 · Cited by 1
“This issue is particularly relevant in the context of rapid diagnostic tests, including LFIA, which are increasingly used to identify carbapenemases and enable early initiation of appropriate therapy in bloodstream infections [25–27].”
Afzaruddin, S. S., Ishak, N. H., Hamid, S. B. S., Ismail, Z., & Shabani, N. R. M. (2026) · Biochimie · doi:10.1016/j.biochi.2026.06.014 · Cited by 1
Peng, Y., & Peng, R. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1863232 · Cited by 1
“Its activity against CRAB is generally lower than that of tigecycline (23), and other potential alternatives (e.g., minocycline) were not available.”
Yang, F., Sun, Y. Y., Chen, W., Shen, D., Zhu, J. F., Sun, Z., Cai, Y., Zhang, Y., Shen, H., Sun, F., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01095-26 · Cited by 1
Gao, S., Lu, Y., & Qiao, Q. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.109023 · Cited by 1
Mohammad, S., Ghazal, H., Daly, E. E., Alkhateeb, F., Dawoud, T. H., Hassani, Z. A., Saleem, A., Hassani, A. A., & Almangour, T. A. (2026) · Infection · doi:10.1007/s15010-026-02932-6 · Cited by 1
Sun, R., Cao, X., & Sun, Q. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s627852 · Cited by 1
Raeesian, S., Mardani, S., Castillo, O., Ravella, S., & Torres, L. (2026) · Cureus · doi:10.7759/cureus.116151 · Cited by 1
Vossius, G., Meex, C., Moerman, F., Thys, M., Ernst, M., Bourgeois, M.-E., Wagner, L., Delahaye, T., & Darcis, G. (2023) · Pathogens · doi:10.3390/pathogens12091152 · Cited by 1
“If 3GCs are to be avoided, IDSA guidelines recommend primarily 4GCs (such as cefepime) and carbapenems [9].”
BackgroundInfluentialVivo, A., Fitzpatrick, M. A., Suda, K. J., Wilson, G., Jones, M., Evans, M. E., & Evans, C. T. (2023) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2023.500 · Cited by 1
Rapidly Progressing Skin Lesion in Previously Healthy 5 Month Old
Kambhampati, O., Scheiner, A., Noor, A., El-Chaar, G. M., Canter, M., & Coren, C. V. (2024) · Clinical Pediatrics · doi:10.1177/00099228231221889 · Cited by 1
Liu, T., Zhou, J., Liu, X., & Xu, X. (2024) · Intelligent Pharmacy · doi:10.1016/j.ipha.2024.01.004 · Cited by 1
Eternal Hunt: Unravelling the Challenge of CRE, the Quest for Perfection Continues!
Kannan, A., Jindal, A., & Salotagi, S. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24639 · Cited by 1
Costantino, V., Principe, L., Mehat, J. W., Busetti, M., Piccirilli, A., Perilli, M., Luzzati, R., Zerbato, V., Meliadò, A., Ragione, R. M. L., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13060526 · Cited by 1
“Cefiderocol is listed as an alternative option [6].”
BackgroundTrends in Carbapenem Resistance from 2018-2023 in Home Health Care: The Bottom of the Iceberg
Grassie, S. S., & Ünalan-Altıntop, T. (2024) · The Turkish Journal of Geriatrics · doi:10.29400/tjgeri.2024.392 · Cited by 1
“In cases of non-hospitalized infections selecting an appropriate antibiotic can be challenging because of bacterial resistance (9).”
BackgroundOda, K., Jono, H., & Saito, H. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001240 · Cited by 2
Rachina, S. A., Fedina, L. V., Alkhlavov, A. A., Gasanova, D., Zainalabidova, K. G., Koval, A. A., Burmistrova, E. N., Savochkina, Y. A., Sychev, I. N., Kuleshov, V. G., et al. (2024) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2024.1.104-112 · Cited by 1
Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition
Pourcq, J. T. D., Riera, A., Gras-Martín, L., Garín, N., Busquets, M. A., Cardenete, J., Cardona, D., & Riera, P. (2024) · Pharmaceuticals · doi:10.3390/ph17070896 · Cited by 1
“To select the CT infusion rates to be tested, we followed the Zerbaxa ® SPC [1] and the bibliographic review [2,3,33,34].”
BackgroundMethodLane, L. C., & Hill, D. M. (2024) · Pathogens · doi:10.3390/pathogens13080628 · Cited by 1
“…of America as difficult-to-treat pathogens include: ESBL-producing en-terobacterales, AmpC-producing enterobacterales, carbapenem-resistant enterobacterales, multidrug-resistant (MDR) Pseudomonas aeruginosa , carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia [7].”
BackgroundEvaluating the frequency and risk factors of multidrug-resistant bacteria in biliary samples
Yıldız, M., Büyükkörük, M., Arslan, S., Gokalp, U., Bostancı, H., Dikmen, K., Büyükkasap, Ç., Özger, H. S., & Dizbay, M. (2024) · Iranian Journal of Microbiology · doi:10.18502/ijm.v16i4.16307 · Cited by 1
“This risk varies according to the used antibiotic classes (14-16).”
BackgroundTian, X., Lin, J., Zhou, M., Ge, Y. C., Li, T., Zhang, L., & Liu, Z. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s473088 · Cited by 1
“8 9–11 Moreover, it also mentioned that ampicillin-sulbactam combined with TGC or cefiderocol was the preferred treatment for CRAB-associated pneumonia.”
BackgroundMethodImpact of pharmacist-led aminoglycoside stewardship: a 10-year observational study
Shinoda, Y., Ohashi, K., Matsuoka, T., Arai, K., Hotta, N., & Usami, E. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00399-x · Cited by 1
Li, M., Liu, D., Bergen, P. J., Liang, S., Chen, J., Kho, Z. Y., Lu, J., Sun, H., Hong, W., Liu, X., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40893 · Cited by 2
Shettar, S. R., Sumana, M. N., Shetty, M. S., Maheshwarappa, Y. D., Reddy, R., Srinivasan, A., Dharan, V. P., Kalyatanda, G., Veerabhadra, S. G. S., & Eshwarappa, C. S. (2025) · Frontiers in Transplantation · doi:10.3389/frtra.2024.1494016 · Cited by 1
Phan, C., Tsai, K., Gill, C. M., Chamberland, R. R., Hendrix, C., & Hou, R. (2025) · Case Reports in Infectious Diseases · doi:10.1155/crdi/8155592 · Cited by 1
“Traditionally, carbapenems have been the preferred treatment of ESBL-producing Enterobacterales [3, 4].”
Yan, A., Pan, X., Li, S., Hu, Y., Zhang, H., Li, D., & Huang, L. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s509782 · Cited by 1
“16,17 The selection of these variables referred to the guidelines 8,18 and clinical research.”
Marzella, N., Kish, T. D., Costinaș, C.-S., Dima, L., & Nguyen, T. K. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001934 · Cited by 1
Natarelli, N., Aslam, S., & Greene, J. N. (2025) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001444 · Cited by 1
Bell, C. S., Chaffee, R., Lou, U. Y., Luk, S. O., & Tavares, E. (2025) · Springer eBooks · doi:10.1007/978-3-031-77335-8_35 · Cited by 1
Bezerra, N. F. (2025) · Brazilian Journal of Health Review · doi:10.34119/bjhrv8n4-047 · Cited by 1
Otake, S., Yamagishi, T., Shiomoto, T., Nakashita, M., Kurosu, H., Ikenoue, C., Kato, H., Fukusumi, M., Shimada, T., Takahashi, T., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329635 · Cited by 1
“Furthermore, difficult-to-treat resistance P. aeruginosa (DTRP) was defined in 2018, with a focus on the lack of effective first-line drugs [34–36].”
Assimakopoulos, S. F., & Marangos, M. N. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae196 · Cited by 1
Trương, T. P., Tran, T. T., Le, P. M., Nguyen, V. T., Ta, T. K., Trần, T. T., Le, P. M. D., Tran, C. T., Nguyen, Q. T., & Nguyen, T. T. (2025) · Research Square · doi:10.21203/rs.3.rs-6195495/v1 · Cited by 1
Yi, S. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.04.043 · Cited by 1
Maraolo, A. E., & Ceccarelli, G. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf533 · Cited by 1
Changing Genotypes and tetB Carriage in CRAB in Korean Children — Implications for Minocycline Use
Yun, K. W., Kang, H. M., Lee, J., & Kim, Y. (2025) · Infection and Chemotherapy · doi:10.3947/ic.2025.0067 · Cited by 1
“Given the limited therapeutic options for CRAB and the potential role of high-dose sulbactam–minocycline combinations, continuous monitoring of molecular epidemiology is essential [4-6].”
New Delhi Metallo-β-Lactamase in Fresh Lung Transplant
Schubert, P. (2021) · Cohesive Journal of Microbiology & Infectious Disease · doi:10.31031/cjmi.2021.05.000606
Correal, J. C. D., Unser, B. M., Cunha, J. V. S., Dias, M. L. S., Ledesma, L. A., & Damasco, P. V. (2023) · Open Access Journal of Science · doi:10.15406/oajs.2023.06.00196
Lloyd, T., Gill, C. M., Herrera, J. A., Heaton, D., Shemsu, M., Trivedi, K. K., Gorzalski, A. J., Bender, M., Pandori, M., Varghese, V., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.17.567598
CẬP NHẬT SỬ DỤNG KHÁNG SINH TRONG NHIỄM KHUẨN GRAM ÂM ĐA KHÁNG THEO HƯỚNG DẪN CỦA IDSA 2023
Võ, T. C., Nguyễn, T. V., Võ, P. M. T., & Ngô, T. Y. N. (2023) · Tạp chí Y Dược học Cần Thơ · doi:10.58490/ctump.2023i67.2195
Acosta-España, J. D., Salazar, C. S., Suaste, K., Luna, C., & Rodriguez-Morales, A. J. (2023) · New Microbes and New Infections · doi:10.1016/j.nmni.2023.101211
Enterobacteriacae resistance to antibiotics and treatment options
Subotić, S., Elez-Burnjaković, N., Ristić, S., Joksimović, B., Stevanović, G., & Kulić, J. (2023) · Биомедицинска истраживања · doi:10.59137/bii202302334s
Hsueh, C.-C., Lai, C., Tsai, Y., Ko, W., & Wang, J. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107087
Federal Oversight of Laboratory-Developed Tests
Singhal, U., Kesselheim, A. S., & Morgan, T. M. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2314290
Traitement des infections dues à des bacilles à Gram négatif en pédiatrie
Cohen, R., Dortet, L., Caséris, M., Raymond, J., Lorrot, M., & Toubiana, J. (2024) · Journal de Pédiatrie et de Puériculture · doi:10.1016/j.jpp.2024.04.004
de Lima, A. V. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2024.tde-11032024-153612
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.